A5084028687- Ovarian function and disorders
- Endometriosis Research and Treatment
- Reproductive Biology and Fertility
- Reproductive Health and Technologies
- Assisted Reproductive Technology and Twin Pregnancy
- Uterine Myomas and Treatments
- Medical and Health Sciences Research
- Gynecological conditions and treatments
- Reproductive System and Pregnancy
- Demographic Trends and Gender Preferences
- Hypothalamic control of reproductive hormones
- Biosimilars and Bioanalytical Methods
- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Medical History and Research
- Health Systems, Economic Evaluations, Quality of Life
- Reproductive Physiology in Livestock
- Maternal and fetal healthcare
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Historical Studies on Reproduction, Gender, Health, and Societal Changes
- Skin Diseases and Diabetes
- Mental Health and Psychiatry
- Personality Traits and Psychology
- Hair Growth and Disorders
- Animal health and immunology
Friedrich Schiller University Jena
2018-2023
Jena University Hospital
2018-2023
Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin
2020-2023
Klinik für Frauenheilkunde
1991-2023
European Society of Human Reproduction and Embryology
2013-2014
Ludwig-Maximilians-Universität München
2010
Repha (Germany)
2010
Pomeranian Medical University
2004
Reproduktionsmedizin München
2004
Heidelberg University
2000
The 14th European IVF—monitoring (EIM) report presents the results of medically assisted reproduction treatments including reproductive technology (ART) cycles and intrauterine insemination (IUI) initiated in Europe during 2010: are there changes trends compared with previous years? Despite some fluctuations number countries reporting, overall ART has continued to increase year by year, while pregnancy rates 2010 remained similar those reported 2009, transfers multiple embryos (three or...
The 13th European in vitro fertilization (IVF)-monitoring (EIM) report presents the results of treatments involving assisted reproductive technology (ART) initiated Europe during 2009: are there any changes trends compared with previous years?Despite some fluctuations number countries reporting data, overall ART cycles has continued to increase year by and, while pregnancy rates 2009 remained similar those reported 2008, transfers multiple embryos (3+) and delivery declined.Since 1997, data...
Abstract The prolonged lockdown of health services providing high-complexity fertility treatments –as currently recommended by many reproductive medicine entities– is detrimental for society as a whole, and infertility patients in particular. Globally, approximately 0.3% all infants born every year are conceived using assisted technology (ART) treatments. By contrast, the total number COVID-19 deaths reported so far represents 1.0% expected to occur worldwide over first three months current...
This article represents a viewpoint on the POSEIDON criteria by group of clinicians and embryologists. Its primary objective is to contextualize Poseidon their metric success for relevant Frontiers Research Topic "POSEIDON's Stratification Low Prognosis Patients in ART: The WHY, WHAT, HOW". "Low prognosis" relates with reduced oocyte number, which can be associated low or sometimes normal ovarian reserve aggravated advanced female age. These aspects will ultimately affect number embryos...
An observational, matched, case–control study was carried out to compare the efficacy of recombinant human luteinizing hormone (r-hLH) supplementation with that urinary menopausal gonadotrophin (u-hMG)-based LH activity during controlled ovarian stimulation (COS) for assisted reproductive technology (ART) using a long gonadotrophin-releasing (GnRH)-agonist protocol. A total 4719 women, 1573 per group, matched by age, body mass index, indication and number previous ART cycles, were treated...
Abstract Endometriosis affects a significant number of young premenopausal women. Quite apart from the medical challenges, endometriosis is relevant burden for healthcare and social security systems. Standardized quality indicators treatment have not previously been systematically verified. The three-stage study QS ENDO was initiated to record improve reality care. One its aims create diagnosis endometriosis. For first stage Real, letters were sent all 1014 gynecological departments in...
Objectives: To perform a cost-effectiveness evaluation comparing the originator follitropin alfa (Gonal-f ® ) to biosimilar (Bemfola in Italian and Spanish contexts, with an assessment of German UK backgrounds. Methods: Starting from study by Rettenbacher et al, model was developed contexts. Clinical data on subjects, doses gonadotropin, pregnancies, live-born children, ovarian hyperstimulation syndrome were used feed model. Costs related drugs, hospitalizations, specialist visits,...
Background and objectives: Demand for assisted reproduction technology (ART) in Germany is high, with 100,844 treatment cycles during 2016. Many ART procedures involve ovarian stimulation follicle stimulating hormone (FSH). Recently, biosimilar FSH products have become available. The objective of this study was to evaluate the cost-effectiveness recombinant Gonal-f® (Originator) comparison follitropin alfa, Bemfola® (Biosimilar 1) Ovaleap® 2), from a German payer perspective terms cost per...
Gonadotropin treatment has been used in fertility since the 1930s. First, preparations coming from animals were injected, then, gonadotropins prepared pituitary glands of human cadavers. A great step was achieved with introduction menopausal gonadotropin extracted urine postmenopausal women. When cases Creutzfeld-Jacob disease recognized after use pituitary-derived hormone injections, urinary increasingly purified and then produced by recombinant DNA technology. Recombinant characterized...
Abstract Background This study compared the effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa; GONAL-f ® ) with urinary highly purified menopausal gonadotropin (hMG HP; Menogon HP ), during assisted reproductive technology (ART) treatments in Germany. Methods Data were collected from 71 German fertility centres between 01 January 2007 and 31 December 2012 , for women undergoing a first stimulation cycle ART treatment r-hFSH-alfa or hMG HP. Primary outcomes...
Although biosimilar drugs may be cheaper to purchase than reference biological products, they not the most cost-effective treatment achieve a desired outcome. The analysis reported here compared overall costs live birth using follitropin alfa (GONAL-f) or (Ovaleap) in Spain, Italy and Germany.Patient data was obtained from published sources; assisted-reproductive technology, gonadotropin, follow-up adverse-event-related were calculated tariffs reimbursement frameworks for each country....
Background. A 2:1 (150 IU:75 IU) follitropin alfa:lutropin alfa formulation has been developed. 3-year post-marketing surveillance study is ongoing in Germany to explore the use of this routine clinical practice.
Follicle-stimulating hormone (FSH) and luteinizing (LH) both have a role to play in follicular development during the natural menstrual cycle. LH supplementation controlled ovarian stimulation (COS) for assisted reproductive technology (ART) is used patients with hypogonadotropic hypogonadism. However, use of exogenous COS normogonadotropic women undergoing ART subject debate. The aim this study was investigate characteristics infertile who received 2:1 formulation follitropin alfa lutropin...
This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary menopausal gonadotropin (hMG-HP), based on data from German in vitro fertilization registry (RecDate). Pregnancy and rates RecDate study over three complete assisted reproductive technology (ART) cycles using same drug were used as clinical inputs. Costs related to ART treatment drugs obtained public...